The Pathology and Laboratory Support Core is an effective nucleus that supports the various studies of the program project by providing routine and advanced technical preparations, including morphological analysis of cells, tissue and organ preparations. The core provides diagnostic light microscopic evaluation, epifluorescent microscopy of histological sections and immunohistochemical interpretation of human and murine prostatic tissue and prostate cancer bone metastases. In addition, technologically advanced expert assistance in a broad range of methods, including quantitative RT-PCR and tissue in-situ hybridization are available. Program project investigators utilizing animal necropsies also have access to sophisticated techniques, such as transmission electron microscopy and image analysis/morphometry. Facilities available include histology (special stains, frozen, paraffin- and plastic-embedded sections) and immunohistochemistry. A key advantage of the core is that it enables unified characterization and dissemination of a shared set of histologic standards. Key to the study of the tumor-bone-stromal interaction is the ability to isolate relatively pure samples of the tumor and the surrounding stroma. Particularly relevant to our program project is the ability to do so in the primary tumor as well as in bone specimens with metastasis.The pathology core will a) procure fresh prostatic tissue, including: primary tumor, tumor-related stroma, benign epithelium, metastatic bone specimens, and stroma unrelated to tumor from clinical specimens under direct morphologic visualization using laser capture microscopy for molecular analyses;b) serve as the morphology core, providing prostate cancer diagnostic expertise for both clinical specimens and animal models of prostate cancer, maintain frozen section and light microscopic facilities, histochemistry, immunohistochemistry and in situ hybridization microscopic support;and c) provide ample well-characterized, archived pathologic samples for screening of candidate molecules of potential mechanistic importance, validation of cell culture and animal model experimental data anddiscovery of novel biomarkers, including high throughput analysis - tissue microarray.
Core C will continue to provide both diagnostic and molecular analysis of cell and tissue samples from human and animals. This will allow for more comprehensive quality testing with wider variety of advanced methods. Procedures are standardized and quality-controlled, leading to greater technical uniformity and allowing for direct comparisons between projects. Investigators will continue to have ready access to sophisticated techniques such as transmission electron microscopy and image analysis.
|Li, Xiangyan; Chen, Yi-Ting; Hu, Peizhen et al. (2014) Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther 13:855-66|
|Miles, Fayth L; Sikes, Robert A (2014) Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res 12:297-312|
|Warren, Curtis R; Grindel, Brian J; Francis, Lewis et al. (2014) Transcriptional activation by NF?B increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironment. J Cell Biochem 115:1322-33|
|Shao, Chen; Liao, Chun-Peng; Hu, Peizhen et al. (2014) Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer. PLoS One 9:e88967|
|Pradhan-Bhatt, Swati; Harrington, Daniel A; Duncan, Randall L et al. (2014) A novel in vivo model for evaluating functional restoration of a tissue-engineered salivary gland. Laryngoscope 124:456-61|
|Shi, Changhong; Wu, Jason Boyang; Chu, Gina C-Y et al. (2014) Heptamethine carbocyanine dye-mediated near-infrared imaging of canine and human cancers through the HIF-1?/OATPs signaling axis. Oncotarget 5:10114-26|
|Tighiouart, Mourad; Piantadosi, Steven; Rogatko, André (2014) Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control. Stat Med 33:3815-29|
|Fong, Eliza L S; Martinez, Mariane; Yang, Jun et al. (2014) Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Mol Pharm 11:2040-50|
|Tighiouart, Mourad; Liu, Yuan; Rogatko, André (2014) Escalation with overdose control using time to toxicity for cancer phase I clinical trials. PLoS One 9:e93070|
|Josson, Sajni; Gururajan, Murali; Hu, Peizhen et al. (2014) miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res 20:4636-46|
Showing the most recent 10 out of 126 publications